Sign In
Buy AXSM
$233.49
+11.33 (+5.10%)
At Close: Jun 03, 2026
3 Growth Stocks to Buy and Hold
08:00am, Saturday, 13'th May 2023
Axsome's relatively new approval was only the first step in an exciting growth story. Eli Lilly has a strong pipeline that will help improve its already-solid financial results.
2 Magnificent Growth Stocks You Can Buy With $150 Right Now
05:11am, Wednesday, 10'th May 2023
Investing in growth stocks can be far less risky if you make smaller, more frequent purchases of your favorite companies. Axsome Therapeutics is a commercial-stage drugmaker that recently launched a n
Axsome's New Drug Is Scoring a Win. Is the Stock a Buy?
03:37pm, Tuesday, 09'th May 2023
Axsome launched its first in-house developed drug last year -- the antidepressant Auvelity. In its first full quarter of commercialization, Auvelity reached more than 30,000 patients.
Axsome (AXSM) Q1 Earnings Beat Estimates, Auvelity Volume Rises
10:42am, Tuesday, 09'th May 2023
Axsome (AXSM) incurs a narrower-than-expected loss in 1Q23. Its revenues beat estimates and stock gains.
Axsome Therapeutics, Inc. (AXSM) Q1 2023 Earnings Call Transcript
02:22pm, Monday, 08'th May 2023
Axsome Therapeutics, Inc. (NASDAQ:AXSM ) Q1 2023 Earnings Conference Call May 8, 2023 8:00 AM ET Company Participants Mark Jacobson - Investor Relations Herriot Tabuteau - Chief Executive Officer Nick
Axsome Therapeutics (AXSM) Reports Q1 Loss, Tops Revenue Estimates
09:54am, Monday, 08'th May 2023
Axsome Therapeutics (AXSM) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $1.13. This compares to loss of $1.03 per share a year ago.
Axsome Surges As Its Newest Product Shines. But BioXcel Does The Opposite.
09:25am, Monday, 08'th May 2023
Shares of Axsome Therapeutics and BioXcel Therapeutics diverged Monday after the duo reported first-quarter sales of their newest products. The post Axsome Surges As Its Newest Product Shines.
Axsome Therapeutics: Things Are Coming Together Nicely
02:08pm, Tuesday, 02'nd May 2023
Axsome Therapeutics, Inc. has a lot of good things happening. Axsome Therapeutics has the potential to become a large CNS-focused biopharma.
The 3 Most Promising Biotech Innovations in 2023 and the Stocks to Buy
06:26am, Friday, 28'th Apr 2023
The biotech sector is up 4.76% so far in 2023. This continues the nice run that biotech stocks had in 2022.
Axsome Therapeutics Stock: Bear vs. Bull
05:30am, Sunday, 23'rd Apr 2023
Axsome recently launched two potential blockbusters. At the same time, expenses are rising, and the company's net loss is widening.
3 Stocks With Huge Catalysts on the Way
06:18am, Saturday, 22'nd Apr 2023
Axsome Therapeutics has several major milestones around the corner. CRISPR Therapeutics could soon win approvals for its first product.
Axsome (AXSM) Focuses on Auvelity Launch to Fuel Its Growth
01:43pm, Friday, 21'st Apr 2023
Axsome's (AXSM) earnings benefit from the launch of Auvelity (AXS-05), meant for treating major depressive disorders.
Axsome Therapeutics to Present Five Abstracts Including New Data from the Positive SHARP Study of SUNOSI® (solriamfetol) in Participants with Cognitive Impairment with Excessive Daytime Sleepiness in Obstructive Sleep Apnea at the 2023 American Academy of Neurology (AAN) Annual Meeting
07:00am, Friday, 21'st Apr 2023
NEW YORK, April 21, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous syste
The Top 3 Biotech Stocks to Watch in 2023
10:07am, Thursday, 20'th Apr 2023
Investors may want to keep an eye on the biotech boom and these top biotech stocks to watch. For one, the sector is still one of the safest, most recession-proof investments around.
2 Beaten-Down Growth Stocks to Buy in April
09:45am, Thursday, 20'th Apr 2023
Axsome is expecting important developments that should improve its already-bright prospects. Tandem's innovative insulin pump should allow it to capture a larger share of the diabetes market.
